Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Current Allergy and Asthma Reports
Erschienen in: Current Allergy and Asthma Reports 8/2015

01.08.2015 | Rhinitis (JJ Oppenheimer and J Corren, Section Editors)

The Future of Sublingual Immunotherapy in the United States

verfasst von: Nicole Pleskovic, Ashton Bartholow, Deborah A. Gentile, David P. Skoner

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Sublingual immunotherapy (SLIT) is a safe and effective treatment for allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC). The Food and Drug Administration (FDA) in the USA has approved three SLIT tablets for the treatment of AR and ARC in relation to pollen. Specifically, Grastek® and Oralair® are two formulations approved to treat patients suffering with AR/ARC to grass pollen, and Ragwitek™ is a formulation approved to treat patients suffering with AR/ARC to ragweed pollen. Although these approvals provide support for physicians to prescribe SLIT, barriers to prescribing SLIT still remain such as FDA approval for additional formulations, a standard dose and dosing schedule, and cost/insurance coverage. In order to further support the use of SLIT, research is currently being conducted to expand the indication for SLIT to other common comorbidities to AR/ARC. For example, allergic asthma, food allergies, and atopic dermatitis are other diseases which are being explored. The future of SLIT in the USA is unknown; however, education will be necessary for both providers and patients.
Literatur
1.
Gentile D, Bartholow A, Valovirta E, Scadding G, Skoner D. Current and future directions in pediatric allergic rhinitis. J Allergy Clin Immunol Pract. 2014;1:214–26.CrossRef
2.
3.
Lin SY. Sublingual immunotherapy: current concepts for the U.S. practitioner. Int Forum Allergy Rhinol. 2014;4:S55–9.PubMedCrossRef
4.
Brehler R, Klimek L, Kopp MV, Christian Virchow J. Specific immunotherapy-indications and mode of action. Dtsch Arztebl Int. 2013;110:148–58.PubMedCentralPubMed
5.
Linkov G, Toskala E. Sublingual immunotherapy: what we can learn from the European experience. Curr Opin Otolaryngol Head Neck Surg. 2014;22:208–10.PubMedCrossRef
6.
Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy world allergy organization position paper. WAO J. 2009;2:233–81.
7.•
Kim JM, Lin SY, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics. 2013;131:1155–67. The authors performed a meta-analysis to study SLIT and the therapy’s effectiveness and safety in asthmatics, rhinitis, conjunctivitis, and children.PubMedCentralPubMedCrossRef
8.
Nelson HS. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? J Allergy Clin Immunol Pract. 2014;2:144–9.PubMedCrossRef
9.•
Didier A, Wahn U, Horak F, Cox LS. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Expert Rev Clin Immunol. 2014;10:1309–24. This article summarizes all key parts of grass pollen SLIT including the formulations Oralair® and Grazax™/Grastek® from their efficacy, safety, research trials, and cost-effectiveness.PubMedCrossRef
10.••
Creticos PS, Corren J, Feldweg AM. Sublingual immunotherapy for allergic rhinoconjunctivitis and asthma. UpToDate. 2014. This article evaluates SLIT completely—from the background to different formulations. It is an all-encompassing article highlighting delivery formulations, doses, and concomitant diseases. The article also goes into detail regarding the FDA-approved SLIT formulations.
11.
Tucker MH, Tankersley MS. Perception and practice of sublingual immunotherapy among practicing allergists. Ann Allergy Asthma Immunol. 2008;101:419–25.PubMedCrossRef
12.
Sikora JM, Tankersley MS. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: a follow-up survey. Ann Allergy Asthma Immunol. 2013;110:194–7.PubMedCrossRef
13.
Ryan MW, Marple BF, Leatherman B, et al. Current practice trends in allergy: results of a United States survey of otolaryngologists, allergist-immunologists, and primary care physicians. Int Forum Allergy Rhinol. 2014;4:789–95.PubMedCrossRef
14.••
Leatherman B, Skoner DP, Hadley JA, et al. The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) survey: provider practices and beliefs about allergen immunotherapy. Int Forum Allergy Rhinol. 2014;4:779–88. The AIRS surveys collected important knowledge of both providers and patients about AR/ARC and immunotherapy. The article highlights the view of providers on allergen immunotherapy.PubMedCrossRef
15.
16.
Durham SR, Nelson HS, Nolte H, et al. Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. Allergy. 2014;69:617–23.PubMedCentralPubMedCrossRef
17.
Nelson HS. Sublingual immunotherapy: the U.S. experience. Curr Opin Allergy Clin Immunol. 2013;13:663–8.PubMedCrossRef
18.
Bartholow A, Pleskovic N, Drori J, Skoner DP. Review of the use of sublingual allergen immunotherapy in children. Pediatr Allergy Immunol Pulmonol. 2014;27:3–7.CrossRef
19.
Cox L. Sublingual immunotherapy for aeroallergens: status in the United States. Allergy Asthma Proc. 2014;35:34–42.PubMedCrossRef
20.
Nelson HS. Is sublingual immunotherapy ready for use in the United States? JAMA. 2013;309:1297–8.PubMedCrossRef
21.
Larenas-Linnemann D, Esch R, Plunkett G, et al. Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units. Ann Allergy Asthma Immunol. 2011;107:448–58.PubMedCrossRef
22.
Bousquet J, Khaltaev N, Cruz AA, Denburg J, et al. Allergic rhinitis and its impact on Asthma (ARIA) 2008 update. Eur J Allergy Clin Immunol. 2008;63:Supplement 86, 8–160.
23.
Compalati E, Braido F, Canonica GW. Sublingual immunotherapy: recent advances. Allergol Int. 2013;62:415–23.PubMedCrossRef
24.
Aboshady OA, Elghanam KM. Sublingual immunotherapy in allergic rhinitis: efficacy, safety, adherence, and guidelines. Clin Exp Otorhinolaryngol. 2014;7:241–9.PubMedCentralPubMedCrossRef
25.
Di Bona D, Plaia A, Scafidi V, Leto-Barone MS, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol. 2010;126:558–66.PubMedCrossRef
26.
Corp MS& D. Biologic License Application (BLA) for Timothy grass pollen allergen extract tablet for sublingual use. FDA Brief Doc. 2013.
27.
Nakonechna A, Hills J, Moor J, Dore P, Abuzakouk M. Grazax sublingual immunotherapy in pre–co-seasonal and continuous treatment regimens: is there a difference in clinical efficacy? Ann Allergy Asthma Immunol. 2015;114:63–76.CrossRef
28.
Passalacqua G, Garelli V, Sclifo F, Canonica GW. Sublingual immunotherapy for allergic rhinitis and conjunctivitis. Immunotherapy. 2013;5:257–64.PubMedCrossRef
29.
Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7:6.PubMedCentralPubMedCrossRef
30.
Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011;106:S12–6.PubMedCrossRef
31.•
Dranitsaris G, Ellis AK. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety, and cost. J Eval Clin Pract. 2014;20:225–38. This is a valuable meta-analysis performed on Oralair®, Grazax™, and SCIT. It examines and compares the efficacy, safety, and cost of the three medications.PubMedCrossRef
32.
Incorvaia C, DiRienzo A, Celani C, Makri E, Frati F. Treating allergic rhinitis by sublingual immunotherapy: a review. Ann Ist Super Sanita. 2012;48:172–6.PubMedCrossRef
33.
Hankin CS, Cox L, Bronstone A, Wang Z. Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2013;131:1084–91.PubMedCrossRef
34.•
Hankin CS, Cox L. Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Allergy Clin Immunol. 2014;14:363–70. This article consisted of a cost-analysis of SLIT, tablets and drops, SCIT, and symptomatic drug treatment.PubMedCrossRef
35.
Bender BG, Oppenheimer J. The special challenge of nonadherence with sublingual immunotherapy. J Allergy Clin Immunol Pract. 2014;2:152–5.PubMedCrossRef
36.
Anolik R, Schwartz AM, Sajjan S, Allen-Ramey F. Patient initiation and persistence with allergen immunotherapy. Ann Allergy Asthma Immunol. 2014;113:101–7.PubMedCrossRef
37.
Maloney J, Durham S, Skoner D, et al. Safety of sublingual immunotherapy Timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma. Allergy. 2015;70:302–9.PubMedCrossRef
38.
Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181:116–24.PubMedCentralPubMedCrossRef
39.
Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA. 2013;309:1278–88.PubMedCrossRef
40.
Nowak-Wgrzyn A, Sampson HA. Future therapies for food allergies. J Allergy Clin Immunol. 2011;127:558–73.CrossRef
41.
Boyce JA, Assa’ad A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010;126:S1–S58.PubMedCentralPubMedCrossRef
42.
Kim EH, Bird JA, Kulis M, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2011;127:640–646.e1.PubMedCentralPubMedCrossRef
43.
Fleischer DM, Burks AW, Vickery BP, et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol. 2013;131:119–127.e1-e7.PubMedCentralPubMedCrossRef
44.
Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116:1073–9.PubMedCrossRef
45.
Narisety SD, Frischmeyer-guerrerio PA, Keet CA, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135:1275–82.
46.
Burks AW, Wood RA, Jones SM, et al. Sublingual immunotherapy for peanut allergy: long-term follow-up of a randomized multicenter trial. J Allergy Clin Immunol. 2015;1–12.
47.
48.
Qin YE, Mao JR, Sang YC, Li WX. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. Int J Dermatol. 2014;53:650–5.PubMedCrossRef
49.
Sánchez-Borges M, Asero R, Ansotegui IJ, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J. 2012;5:125–47.PubMedCentralPubMedCrossRef
50.•
Nettis E, Colanardi MC, Soccio AL, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. Br J Dermatol. 2007;156:674–81. This study showed the effects or house dust mite SLIT in adults with allergic rhinitis. The 300IR and 500IR levels show a significant improvement in symptoms after 1 year of treatment, and this effectiveness was maintained in the second year without the therapy.PubMedCrossRef
51.
Bergmann K-C, Demoly P, Worm M, Fokkens W, Carrillo T. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. Am Acad Allergy Asthma Immunol. 2013;133:1608–14.
52.
Cingi C, Bayar Muluk N, Ulusoy S, et al. Efficacy of sublingual immunotherapy for house dust mite allergic rhinitis. Eur Arch Oto-Rhino-Laryngology. 2014.
53.
Trebuchon F, Lheritier-Barrand M, David M, Demoly P. Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens. Clin Transl Allergy. 2014;4:15.PubMedCentralPubMedCrossRef
54.
Aydogan M, Eifan AO, Keles S, et al. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. Respir Med. 2013;107:1322–9.PubMedCrossRef
55.
Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Two year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing subcutaneous and sublingual immunotherapy. Asian Pac J Allergy Immunol. 2013;31:233–41.PubMedCrossRef
56.
Nelson HS. Update on house dust mite immunotherapy: are more studies needed? Curr Opin Allergy Clin Immunol. 2014;14:542–8.PubMedCrossRef
57.
Calderon MA, Casale TB, Nelson HS, Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. Am Acad Allergy Asthma Immunol. 2013;132:1322–36.
58.
Casale TB, Stokes JR. Future forms of immunotherapy. J Allergy Clin Immunol. 2011;127:8–15.PubMedCrossRef
59.
Swamy RS, Reshamwala N, Hunter T, et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol. 2012;130:215–224.e7.PubMedCentralPubMedCrossRef
60.
Amar SM, Harbeck RJ, Sills M, Silveira LJ, O’Brien H, Nelson HS. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol. 2009;124:150–156.e5.PubMedCrossRef
61.
Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2000;105:1108–16.PubMedCrossRef
62.
Creticos PS, Esch RE, Couroux P, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2014;133:751–8.PubMedCrossRef
63.
Antico A. Long-term adherence to sublingual tablet: literature review and suggestions for management strategies based on patients’ needs and preferences. Clin Exp Allergy. 2014;44:1314–26.PubMedCrossRef
64.
Devillier P, Dreyfus J-F, Demoly P, Calderón MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Med. 2014;12:71.PubMedCentralPubMedCrossRef
65.
Skoner D, Blaiss M, Dykewicz M, et al. The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) survey: patients’ experience with allergen immunotherapy. Allergy Asthma Proc. 2014;35:219–26.PubMedCrossRef
Metadaten
Titel
The Future of Sublingual Immunotherapy in the United States
verfasst von
Nicole Pleskovic
Ashton Bartholow
Deborah A. Gentile
David P. Skoner
Publikationsdatum
01.08.2015
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 8/2015
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-015-0545-x

Weitere Artikel der Ausgabe 8/2015

Current Allergy and Asthma Reports 8/2015 Zur Ausgabe

Food Allergy (T Green, Section Editor)

Oral Food Challenges: The Design must Reflect the Clinical Question

Erratum

Erratum to: Technological Innovations for High-Throughput Approaches to In Vitro Allergy Diagnosis

Rhinitis (JJ Oppenheimer and J Corren, Section Editors)

Role of Rhinopharyngoscopy in Diagnosis of Rhinopathies

Rhinosinusitis (J Mullol, Section Editor)

Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients with Chronic Rhinosinusitis

Anaphylaxis and Drug Allergy (DA Khan and M Castells, Section Editors)

Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association

Food Allergy (T Green, Section Editor)

Food Protein-Induced Enterocolitis Syndrome, Allergic Proctocolitis, and Enteropathy

Neu im Fachgebiet HNO

Nur selten Nachblutungen nach Abszesstonsillektomie

03.05.2024 Tonsillektomie Nachrichten

In einer Metaanalyse von 18 Studien war die Rate von Nachblutungen nach einer Abszesstonsillektomie mit weniger als 7% recht niedrig. Nur rund 2% der Behandelten mussten nachoperiert werden. Die Therapie scheint damit recht sicher zu sein.

Rezidivierender Peritonsillarabszess nach Oralsex

02.05.2024 Peritonsillarabszess Kasuistik

Die erotischen Dimensionen von Peritonsillarabszessen scheinen eng begrenzt zu sein. Das heißt aber nicht, solche Abszesse und Erotik hätten nichts miteinander gemein, wie ein Fallbericht verdeutlicht.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise